$ALQAD News: Alliqua Appoints Perry A. Karsen to Board of Directors - CEO of Celgene Cellular Therapeutics To Add Further Depth and Value to Alliqua's Board

LANGHORNE, Pennsylvania, - (http://www.FinancialNewsMedia.com News Alert) - Alliqua, Inc. (OTCQB:ALQAD) (\"Alliqua\" or the \"Company\") has appointed Perry A. Karsen to its Board of Directors, increasing the size of the Board to nine members.



Mr. Karsen, age 58, is Chief Executive Officer of Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene Corporation, for which Mr. Karsen also serves as Executive Vice President and Chief Operations Officer.



Mr. Karsen said, \"Last month, I was pleased to help oversee the licensing of advanced wound care products, Biovance(r) and Extracellular Matrix (ECM), from Celgene Cellular Therapeutics to Alliqua. I am impressed by Alliqua\'s existing suite of wound care products and I look forward to working with Alliqua\'s management as Alliqua expands its sales, marketing and distribution initiatives.\"



David Johnson, Chief Executive Officer of Alliqua, said, \"As part of our transaction with Celgene that was publicly announced on November 19, Celgene received a right to appoint a director to our Board of Directors. I am delighted that Perry Karsen has agreed to assume this role. He possesses a profound knowledge of the wound care space, and has demonstrated a deep commitment to its further development. We are privileged to have him help us as we continue to pursue our corporate goals.\"



About Alliqua, Inc.



Alliqua, Inc. (ALQAD) (\"Alliqua\") is a biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies. Alliqua\'s technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations.



Alliqua currently markets its line of 510(k) FDA-approved hydrogel products for wound care under the SilverSeal(r) brand, as well as the sorbion sachet S and sorbion sana wound care products. Alliqua\'s electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua\'s hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as...